peaceAKKIPlease read ANP ann on 7th Dec, Phase 1 trial was a...

peaceAKKI

Please read ANP ann on 7th Dec, Phase 1 trial was a success. As such, in ANP's case, the chance of success for ATL1103 Phase 1 is in fact 100%. It is no longer a potential but a reality.

Phase 2a is an expansion of Phase 1 but with larger sample in a 12 weeks trial period. Also there could be a parallel trial on actual patients.

ANP is proceeding to PHASE 2, not a potnetial but a certainty.

The fact that Phase 2 has 50% higher success rate than Phase 1 clinical trial should give you the clue that the risk factor is actual half that of Phase 1.

To repeat myself, Pfizer did take over Excalliard at Phase 2 stage. The part investor, ISIS, received $14m as a portion of the total upfront payment for the Stage 2 milestone. EXC001 has only 1/3 of the market size revenue wise as ATL1103.

You are always welcome to post as long as you are clear of what you are posting without any misleading info.